Literature DB >> 18000598

Urotensin-II in the lung: a matter for vascular remodelling and pulmonary hypertension?

Talija Djordjevic1, Agnes Görlach.   

Abstract

Urotensin-II (UII) is an evolutionary conserved peptide which has been initially discovered in the urophysis of the fish goby regulating body fluid composition and vascular tone. Mammalian UII has gained increasing interest since it has been considered as an even more potent vasoconstrictor than endothelin-1, although its efficiency is greatly variable throughout species and vascular beds. More recently, it has been shown that UII, which mediates its action via binding to the G-protein coupled urotensin-II receptor, is not only involved in the regulation of the vascular tone but can also stimulate a variety of signaling cascades in different cells and organs in the body including generation of reactive oxygen species and nitric oxide, activation of MAP kinases, and modulation of gene expression. Indeed, UII can stimulate proliferative processes, affect the extracellular matrix and may even add to a prothrombotic state. Such vascular remodelling processes are, in conjunction with enhanced vasoconstriction, involved in the pathogenesis of pulmonary hypertension, suggesting that UII may play a novel role in the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000598

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

2.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

3.  The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions.

Authors:  D A B Rex; G P Suchitha; Akhina Palollathil; Anagha Kanichery; T S Keshava Prasad; Shobha Dagamajalu
Journal:  J Cell Commun Signal       Date:  2022-02-16       Impact factor: 5.782

4.  Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension.

Authors:  Ahmet Mesut Onat; Yavuz Pehlivan; Ibrahim Halil Turkbeyler; Tuncer Demir; Davut Sinan Kaplan; Ali Osman Ceribasi; Mustafa Orkmez; Ediz Tutar; Seyithan Taysi; Mehmet Sayarlioglu; Bunyamin Kisacik
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

5.  NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II.

Authors:  Isabel Diebold; Andreas Petry; Maximilian Burger; John Hess; Agnes Görlach
Journal:  Mol Biol Cell       Date:  2011-09-30       Impact factor: 4.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.